Pricing & Reimbursement

Scrip and Pink Sheet editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.

Volume gains from the entry into China’s national reimbursement program offset deep price cut for AstraZeneca’s major selling Tagrisso in the second quarter of 2021.

Roche’s Evrysdi debuts in India backed by a patient support program ahead of Novartis’ Zolgensma and Biogen’s Spinraza. Spotlights remains on the price tag for the SMA therapy amid hopes that novel approaches such as crowdfunding could also broaden access.

They may have a good shot at passage given recent actions by President Biden and the Federal Trade Commission, and bipartisan interest in drug pricing. 

Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.

As Democrats in the US Congress work to move legislation empowering the Health and Human Services Department to negotiate drug prices directly with manufacturers, the Center For American Progress releases an analysis on which drugs would be targeted by House bill HR 3 and how much prices could be reduced.

The company anticipates an addressable global market for progressive familial intrahepatic cholestasis of 2,500 patients, with initial plans to focus on around 100 physicians at 60 centers.

The company insists it will reconsider the price of Aduhelm if the market turns out to be larger than Biogen anticipates, but big price reductions for branded drugs are rare.

Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.

The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.

The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.

The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.